Cara Therapeutics, Inc. (CARA)
NASDAQ: CARA · Real-Time Price · USD
4.840
-0.170 (-3.39%)
Jan 31, 2025, 4:00 PM EST - Market closed
Cara Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Cara Therapeutics stock has a target of 12, which predicts an increase of 147.93% from the current stock price of 4.84.
Analyst Consensus: Hold
* Price targets were last updated on Jun 13, 2024.
Analyst Ratings
The average analyst rating for CARA stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $120 → $12 | Strong Buy → Hold | Downgrades | $120 → $12 | +147.93% | Jun 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 13, 2024 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +1,139.67% | May 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $43 | Strong Buy | Reiterates | $43 | +792.56% | May 15, 2024 |
Financial Forecast
Revenue This Year
4.90M
from 20.97M
Decreased by -76.65%
Revenue Next Year
3.67M
from 4.90M
Decreased by -25.00%
EPS This Year
-1.31
from -26.28
EPS Next Year
-0.79
from -1.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 5.0M | 3.8M | 1.6M | |
| Avg | 4.9M | 3.7M | 1.5M | |
| Low | 4.7M | 3.5M | 1.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -76.0% | -22.8% | -57.1% | |
| Avg | -76.7% | -25.0% | -58.3% | |
| Low | -77.6% | -27.9% | -60.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.18 | -0.36 | -0.34 | |
| Avg | -1.31 | -0.79 | -0.65 | |
| Low | -1.35 | -1.11 | -1.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.